Director Sells Thousands of TransMedics Shares in Major Transaction!

New insider activity at TransMedics Group ( (TMDX) ) has taken place on May 14, 2025.

Director Edward M Basile recently sold 6,000 shares of TransMedics Group stock, amounting to a total transaction value of $693,780.

Recent Updates on TMDX stock

TransMedics Group recently reported strong Q1 2025 financial results, with a notable 48% year-over-year revenue increase to $143.5 million, driven by strategic advancements and robust growth in the U.S. market. The company raised its full-year revenue guidance to between $565 million and $585 million, reflecting confidence in its growth trajectory and operational execution. Analysts have responded positively, with TD Cowen, Oppenheimer, and Piper Sandler all raising their price targets for TransMedics. The upgrades are attributed to the company’s significant Q1 beat, raised revenue guidance, and continued operating strength, which are expected to counteract recent negative predictions from short-sellers. The company’s strategic focus on the Organ Care System and National OCS Program, along with upcoming clinical program launches, are seen as key drivers for future growth, despite challenges in international markets and service margins.

Spark’s Take on TMDX Stock

According to Spark, TipRanks’ AI Analyst, TMDX is a Outperform.

TransMedics Group shows strong financial performance with impressive revenue growth and a transition to profitability, which are significant strengths. The technical analysis indicates positive momentum, though the stock might be overbought. The high P/E ratio suggests overvaluation, and while the earnings call was largely positive, some challenges were noted. Overall, the company is on a positive trajectory but faces certain risks that should be monitored.

To see Spark’s full report on TMDX stock, click here.

More about TransMedics Group

YTD Price Performance: 78.54%

Average Trading Volume: 1,226,856

Technical Sentiment Signal: Strong Buy

Current Market Cap: $4.02B